Search results for: Health Care Systems
Filter search results
2019 OHE Annual Report to the Charity Commission
1 December 2020
…advancing the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy; and using health economics methods to produce evidence-based health…
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
…not address the systemic problems with the US healthcare system. What is the problem in US health care? The US is recognised as providing rapid access for many citizens to…
OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’
18 December 2024
…of medicines or pharmaceutical specialities to be based on transparent and objective criteria. Professor Cookson’s response proposes a value-based approach to pricing, which would allow: • Healthcare systems to appropriately reward…
OHE Lunchtime Seminar on 29 April 2015: Do Financial Incentives Trump Clinical Guidance? Hip Replacement in England and Scotland
24 March 2015
…are focused on performance measurement, international comparisons of health systems and performance based payment systems. Professor Alistair McGuire is a Professor in Health Economics at LSE Health and Social…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…top of the initial payment for manufacturing and distribution of the product. Being optional, this alternative, flexible, instrument would delink prices, allowing health systems and payers to initially purchase new…
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
…technology assessment (HTA) decisions are implemented by national health systems. Our analysis found that since the implementation of the OMP Regulation, 143 OMPs have obtained marketing authorisation in the EU. These…
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
…systematic undervaluation of their contributions across health systems. AMR diagnostics are not consistently or comprehensively assessed through value assessment or reimbursement frameworks, meaning their broader societal and population-level benefits are…
An Insurance Framework for Funding New Antibiotics
22 September 2017
…Goodall, Mark Hirsch, and John Rex. Healthcare systems depend on the availability of new antibiotics. However, there is a lack of treatments for infections caused by multidrug resistant (MDR) pathogens…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
…histology. The path from regulatory approval to patient access remains highly variable and complex across jurisdictions. Regulatory, HTA and reimbursement approaches vary widely across key national health systems. Diagnostic access…